Keywords: prepare, study, shows, amgen, aranesp, does, enhance
PREPARE study shows Amgen's Aranesp does not enhance pre-surgery chemo
Article | 10 December 2007
World biotechnology giant Amgen has received disappointing interim results from the PREPARE study, an open-label, randomized, multicenter Phase III trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
